P21
Small peptide derived from ciliary neurotrophic factor (CNTF) — designed to cross the blood-brain barrier and enhance neurogenesis and synaptic plasticity without the appetite-suppressing effects of full CNTF.
🔬 Mechanism of Action
P21 (also called P021) is a small peptide derived from the active region of ciliary neurotrophic factor (CNTF) — a neurotrophic cytokine that supports neuronal survival but causes severe appetite suppression and cachexia when administered systemically.
P21 was designed to retain CNTF's neurogenic benefits while eliminating appetite-suppressive effects. It achieves this through a dual mechanism: (1) inhibiting leukemia inhibitory factor (LIF) signaling — the pathway responsible for CNTF's metabolic side effects, and (2) enhancing BDNF expression and adult hippocampal neurogenesis through a CNTF receptor-independent pathway.
In Alzheimer's disease models (3xTg-AD mice), P21 reduced tau hyperphosphorylation by 50-60%, increased hippocampal neurogenesis by 3-fold, and prevented synaptic loss. It crosses the blood-brain barrier via both subcutaneous and intranasal routes, making it one of the most promising peptides for neurodegenerative disease intervention.
Source: PMID: 23877024
📜Background & History
P21 (P021) emerged from the lab of Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities. The peptide was rationally designed from CNTF's active region to retain neurogenic properties while eliminating the appetite suppression (cachexia) that prevented full CNTF from clinical use. In 3xTg-AD mice (triple transgenic Alzheimer model), P21 reduced tau phosphorylation by 50-60%, increased hippocampal neurogenesis 3-fold, and prevented synaptic loss. These are the most impressive pre-clinical results for any neurogenic peptide targeting Alzheimer pathology.
🎯 Research Use Cases
- ✓Neurodegenerative disease research (Alzheimer, Parkinson, TBI)
- ✓Adult hippocampal neurogenesis enhancement
- ✓Cognitive enhancement and memory formation
- ✓Neuroprotection in aging protocols
💉 Dosing Protocol
| Typical Dose | 500-2000 mcg/day (SC or intranasal) |
| Frequency | 1× daily |
| Half-Life | ~2-4 hours (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Research compound — limited human data. No appetite suppression unlike parent molecule CNTF. Well-tolerated in animal studies at therapeutic doses. Monitor for injection site reactions. Avoid combination with other neurotrophic agents without medical supervision.
⚡Interactions & Contraindications
Research compound with limited human data. No known drug interactions, but theoretical caution with other neurotrophic agents (overlapping BDNF elevation). Monitor for CNS overstimulation when stacking with multiple nootropics.
🔗Synergies & Common Stacks
P21 drives neurogenesis (new neuron growth) while Semax enhances synaptic plasticity in existing neurons — complementary BDNF/NGF upregulation pathways without mechanistic overlap.
Cortexin provides broad neuropeptide support and membrane stabilization while P21 specifically drives hippocampal neurogenesis — complementary neuroprotective approaches.